BrightSpring Q2 EBITDA +44%: Growth Momentum Intact, But Valuation Leaves No Margin of Safety

What happened

BrightSpring reported Q2 revenue growth of 23% and adjusted EBITDA growth of 44%, prompting management to raise full-year 2026 guidance for both revenue and EBITDA, as highlighted in a Seeking Alpha article. This follows Q1's similar performance (revenue +25.6%, EBITDA +44.8%) but the master report notes that Q1's growth was driven by specialty/infusion mix rather than volume, with total pharmacy scripts declining ~1% and Home & Community Pharmacy revenue down 9.2% due to IRA pressure, while Pharmacy Solutions SG&A rose 35.7%. The Q2 results likely continue the mix-led trend, but the article omits details on script volumes and cost discipline, which remain critical watch items for the sustainability of profitability growth. At the current price (~$67.5), valuation is demanding with trailing P/E 44.5 and EV/EBITDA 26.4, though forward multiples decline to 34.4x FY1 P/E and 0.73x PEG, implying the market is pricing in continued rapid earnings growth. The master report's WAIT rating reflects the asymmetry between strong operating momentum and persistent sponsor overhang (KKR still holds ~13.7% after June secondary) and the need for evidence that mix strength can offset policy and cost pressures without structural margin erosion.

Implication

Over the next 3–6 months, monitor quarterly filings for stabilization in Pharmacy Solutions prescriptions dispensed and a reduction in SG&A growth relative to revenue; if those signals appear, the mix-led growth thesis strengthens and the stock could re-rate higher despite valuation. However, if scripts continue to decline and SG&A remains elevated, the operating leverage story falters, and the stock is vulnerable to multiple compression, especially with a potential new KKR secondary after the Aug 2026 lock-up expiry. The raised guidance provides a clearer earnings path, but at current prices the risk-reward is skewed: the base case implied value is ~$68, essentially in line with the market, while the bear case is $58, a 14% downside. Consider trimming positions above $75 and accumulating only near $55, where the margin of safety improves. For traders, the next catalysts are Q3'26 results and any secondary filings, which will determine whether the stock can hold its premium.

Thesis delta

The latest Q2 results confirm strong top-line and EBITDA growth, but do not alter the core thesis that growth is largely mix-driven and faces structural headwinds from IRA pharmacy pricing and rising SG&A. The master report's WAIT rating remains appropriate because the valuation already prices in continued momentum, while sponsor overhang and the lack of volume growth increase downside risk. No change in rating, but the raised guidance slightly reduces uncertainty around near-term earnings, keeping the base case intact.